Featured
Why 'job hugging' is risky in pharma
It's been a tough few years in pharma but this Australian recruitment expert warns that staying put in your current role just for job security is riskier than you think
Regulation & Legal
J&J fails to exclude influencers in class action notice
A court has ruled the channels to inform the public of a class action against Johnson & Johnson can include influencers in order to reach as many people as possible
Patients
Parliament House forum targets faster diagnosis
From 10 months to 10 weeks: national forum held at Parliament house looks to slash diagnosis time for juvenile arthritis in Australia
Government & Policy
Aussie kids missing out on cancer trials
New Medicines Australia white paper calls for reforms to open more potentially life-saving cancer trials to Australian children
Regulation & Legal
Company dobs itself in for UK Code Breach
This company was found to have breached the Code of Practice after it voluntarily reported improperly disclosed grants worth more than $1.3M made more than four years ago
Featured
Meet the lobbyists shaping pharma's future
A new ranking reveals the lobbying firms most used by pharmaceutical companies to press their case with the Government - with one clearly ahead of the pack
Featured
Company launches new leadership role
Created to navigate the increasingly complex landscape of public health priorities, Government policy, public funding and the private market
Jobs
Regulatory & Reimbursement
Pharmas turn up the heat on Novartis
Additional biosimilar brands targeting this lucrative franchise have been approved ahead of the PBAC's meeting next month which will consider them for PBS listing
Industry & Companies
Bayer sets challenge for next-gen innovators
STEM students tackle the impact of climate on Australia’s $100 billion agriculture industry and the trajectory of human health
Jobs & Workplace
Who's left? Senior pharma leaders on the move
Three departures including one redundancy as leaders across industry move on, taking decades of company history with them
Featured
So that's where he's gone: GM lands new job
After a significant stretch as one of industry's longest-serving ANZ Country Leaders this former GM has landed a new role
Regulatory & Reimbursement
Expanded funding for four diabetes drugs
Tens of thousands gain access to diabetes medications after Pharmac expands eligibility for funded treatments
Pipeline & Intellectual Property
Drug dropped over manufacturing issues
All high-strength formulations of this drug are set to be discontinued in Australia, with the TGA implementing Serious Scarcity Substitution to support ongoing patient access
Pipeline & Intellectual Property
Peter Mac spin-off starts life with $12M
The new radiopharma is backed by an investment syndicate led by 'Twiggy' Forrest's Tenmile with a mission to develop significant new medicines for hard-to-treat cancers
Awards
Why this Awards comeback matters
Op-Ed: The return of Healthcare Marketing to Australia's prestigious Effie Awards means so much more than another gong for industry
Industry & Companies
What specialists really think of MSLs
While most specialists view MSLs positively almost a third describe their interactions as average or poor and almost one in three can't spot the difference between an MSL and Sales Rep
Regulatory & Reimbursement
Eczema drug back on PBS listing track
Following an extended back-and-forth with the PBAC, this pharma appears to be progressing its new treatment towards a PBS listing
Industry & Companies
Company cuts ties with reality TV star
DBG Health has severed ties with Sam Wood, who faces two domestic violence charges, after it acquired the reality TV star’s exercise and nutrition program
Featured
'Totally unacceptable': Pharma slammed by UK watchdog
Slapped with the most serious Code of Conduct breach and reprimanded for a "significant failure" on transparency
Pipeline & Intellectual Property
Smaller dose behind bigger profits?
Company catches up with how patients who are using this drug in the real world by kicking off a new trial and the upside could be a hike in profits
Industry & Companies
Moderna enters five-year deal with CSIRO
mRNA powerhouse and Australia's national science agency launched a five-year strategic collaboration at Moderna's Melbourne plant this morning, with the first project unveiled
Industry & Companies
CSL raises $2B but it could come at a cost
The new loans carry an interest rate significantly higher than the ones being replaced
Regulatory & Reimbursement
Drugs slated to exit Australia in 2027
Two well-known cancer drugs that historically generated around $50 million in annual sales each will be removed from the Australian market in the first half of 2027
Regulation & Legal
TGA cracks down dishing $127K in fines
Australia's regulator has handed out a dozen fines for offences involving Eli Lilly's Mounjaro and Olumiant, along with a number of other drugs
Pipeline & Intellectual Property
Archrivals face battle with a new enemy
This newcomer is set to disrupt a longtime rivalry between two Big Pharmas in a highly competitive space after stunning phase 3 results
Regulatory & Reimbursement
Why this therapy must move to an earlier line
Half of the cancer patients who received a one-shot therapy remain progression free after five years, follow-up results show
- Industry & Companies Number of Best Workplaces in Aussie Pharma doubles
- Industry & Companies Jobs go as pharma restructure hits Australia
- Jobs & Workplace Talent on the move: who's up, who's new, who's left
- Industry & Companies Trial failure throws future of pharma into doubt
- Pipeline & Intellectual Property CSL makes $1.7B bet on first-in-class hopeful
- Regulatory & Reimbursement Fourth sponsor enters hot biosimilar market
- Regulatory & Reimbursement First rival but no price cut for $20M drug
- Regulatory & Reimbursement Aussie first hits lucrative market
- Jobs & Workplace Novartis General Manager departs
- Regulatory & Reimbursement First rival triggers price cut for $70M drug